Ariad Pharmaceuticals Inc fka ARIA

[wrkingcapital]

Rida Results
In reviewing median survival figures in patients with metestatic sarcoma I noted that 90% do not survive beyond one year.Wondering if the longer delay between interim 2 and 3 may relate to the secondary end point of overall survival built into the study.

This was important to the FDA as far as trial design... but less so to ARIAD. This may be the cause for delay...evidence of delayed progression is likely to be found earlier than the secondary end point of overall survival...so perhaps that explains the longer interval for results that we are currently experiencing. Any thoughts?